Clinical trial
Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma
NCT00027716 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00027716 |
|---|---|
| Title | Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma |
| Official title | A Multi-Institutional, Open-Label, Two-Group, Phase II Study of PS-341 (LDP-341, NSC #681239) in Patients With Advanced or Metastatic Sarcoma |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Sarcoma |
| Intervention type | Drug |
| Interventions | bortezomib |
| Start date | Oct 1, 2001 |
| Primary completion | May 1, 2004 |
| Completion | May 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 6, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: